Edition:
United Kingdom

Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement


Monday, 8 Jan 2018 

Jan 8 (Reuters) - Resverlogix Corp ::RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT.RESVERLOGIX CORP - ‍UNDER TERMS OF AGREEMENT, MEDISON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET APABETALONE IN ISRAEL​.RESVERLOGIX CORP - CO IS ELIGIBLE TO RECEIVE FROM MEDISON, ASCENDING DOUBLE DIGIT ROYALTIES BASED ON FUTURE NET SALES OF PRODUCT IN REGION.RESVERLOGIX CORP - ENTERED LICENSING AGREEMENT WITH MEDISON PHARMA FOR CO'S LEAD THERAPEUTIC CANDIDATE, APABETALONE IN ISRAEL AND PALESTINE AUTHORITY.RESVERLOGIX CORP - MEDISON WILL BE RESPONSIBLE FOR ALL REGULATORY, SALES AND MARKETING COSTS FOR APABETALONE IN ISRAEL REGION. 

Company Quote

2.78
 --
17 Jul 2019